30 closest matches · ranked by relevance
Recurrent Childhood Ependymoma
Primary: Objective Response Rate (Complete Response Rate and Partial Response Rate) Following Treatment With Everolimus for Children With Recurrent or Progressive Ependymomas…
Anaplastic Ependymoma · Brain Ependymoma · Cellular Ependymoma
Primary: Event-free Survival (EFS) in Children Who Have Completely Resected Ependymoma or Achieved CR and Are Treated With Post-radiation Maintenance Chemotherapy or…
Brain Tumor · Central Nervous System Tumor
Primary: Event-free Survival — 0.614; 0.685; 0.372 Probability of EFS at 5 years
Ependymoma · Anaplastic Ependymoma
Primary: Percentage of Participants That Have Progressive Free Survival (PFS) After 1 Year — 76.4 Percentage of participants
Medulloblastoma · Neuroectodermal Tumor
Primary: 12 Month Progression-free Survival (PFS-12) — 215; 69 Days — p=0.927
Central Nervous System Neoplasms · Medulloblastoma
Primary: Percentage of Participants With an Objective Response and Long-term Stable Disease — 0; 11.1; 10.5; 0 percentage of participants
Glioblastoma Multiforme · Anaplastic Astrocytoma · Anaplastic Oligodendroglioma
Primary: Number of Patients Who Experienced Dose-limiting Toxicities (DLTs) — 3 Participants
Pediatric Recurrent Progressive Low-grade Gliomas · Pediatric Progressive Low-grade Gliomas
Primary: Percentage of Participants With Progression Free Survival at 6 Months — 67 percentage
Brain Tumors
Primary: Progression Free Survival — 70 percentage of no progression
Malignant Glioma · Anaplastic Astrocytoma · Anaplastic Oligoastrocytoma
Primary: Percentage of Participants With Unacceptable Toxicity — 0 percentage of participants
Childhood Cerebellar Anaplastic Astrocytoma · Childhood Cerebral Anaplastic Astrocytoma · Childhood Cerebral Astrocytoma
Primary: Sustained Objective Response Rate — 0; 0 percentage of patients
Brain Tumors · Spinal Cord Tumors
Primary: Time to Progression — 7.8 Months
Brain Cancer · Pediatric Cancers
Primary: Objective Response Rate — 0 Percentage of Participants
Brain and Central Nervous System Tumors
Primary: Progression-Free Survival (PFS) in ERBB2-Negative Tumors Compared to ERBB2-Positive Tumors — 79.2; 83.3; 69.6; 86.7 probability of PFS at 2 years — p=0.8001
Diffuse Intrinsic Pontine Glioma
Primary: Two Year Survival of Pediatric Patients With Diffuse Pontine Gliomas — 14.29 Percentage of patients
Brain Tumors
Primary: Event-free Survival (EFS)
Glioma · Low-grade Glioma · Astrocytoma
Primary: Overall Response — 2; 21 participants
Neurofibromatosis Type 1 · Recurrent Childhood Pilocytic Astrocytoma · Recurrent Childhood Visual Pathway Glioma
Primary: Number of Patients Who Demonstrate Complete or Partial Response — 4; 4 Participants
Osteosarcoma · Medulloblastoma · Sarcoma, Ewing's
Primary: Percentage of Participants With Overall Tumor Response (Response Rate) — 0; 0; 0; 0 Percentage of Participants
CNS Embryonal Tumor, Not Otherwise Specified · Malignant Glioma · Recurrent Atypical Teratoid/Rhabdoid Tumor
Primary: Maximum Tolerated Dose of Ribociclib and Everolimus — 120; 1.2 mg/m^2/day
Central Nervous System Neoplasm · Pineoblastoma · Recurrent Medulloblastoma
Primary: Overall Survival — 2.43; 13.6 percent probability
Adult Diffuse Astrocytoma · Adult Mixed Glioma · Adult Oligodendroglioma
Primary: Progression-free Survival at 6 Months. — 39; 6 Participants
Brain Cancer
Primary: Number of Participants With High-grade Astrocytoma and Diffuse Pontine Tumors Achieving One Year Progression Free Survival. — 5; 6 Participants
Childhood Embryonal Tumor · Childhood Extracranial Germ Cell Tumor · Childhood Extragonadal Germ Cell Tumor
Primary: Event-Free Survival (EFS) — 87.0 Percent probability
Anaplastic Medulloblastoma · Medulloblastoma · Supratentorial Embryonal Tumor, Not Otherwise Specified
Primary: Number of Patients Who Have Either a Complete Response (CR) Rate or No Complete Response Rate — 13; 15; 16; 15 Participants — p=0.35
Recurrent High Grade Meningioma
Primary: Progression Free Survival (PFS) — 4.17; 2.43 Months — p=0.204
Central Nervous System Nongerminomatous Germ Cell Tumor · Childhood Germinoma
Primary: 3-year Progression-free Survival (PFS) Rate of Patients With Nongerminomatous Germ Cell Tumor (NGGCT) Who Were Treated With Reduced Dose Whole Ventricular-field…
Childhood CNS Primitive Neuroectodermal Tumor
Primary: Number of Participants With Objective Response — 3; 1; 1; 7 Participants
Central Nervous System Tumors
Primary: Measurement of Number of Adverse Events — 4; 6; 3; 5 Adverse events
Central Nervous System Tumor, Pediatric · Neuroblastoma
Primary: Therapy Completion Rate — .40 proportion of participants